ASH 2018 | Bispecific mosunetuzumab shows promise in R/R follicular lymphoma and DLBCL

Ian Flinn

Speaking the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition, held in San Diego, CA, Ian Flinn, MD, PhD, of the Tennessee Oncology, Nashville, TN, discusses the CD20/CD3-directed antibody mosunetuzumab in relapsed/refractory B-cell lymphoma (Phase I; NCT02500407). Dr Flinn highlights the promise of this off-the-shelf bispecific antibody.

Share this video